Feasibility and Prognostic Analysis of Neoadjuvant Therapy Followed by Breast-Conserving Surgery for Invasive Ductal Carcinoma Combined with Ductal Carcinoma in Situ.

IF 3.5 4区医学 Q2 SURGERY

Journal of Investigative Surgery Pub Date : 2025-12-01 Epub Date: 2025-09-01 DOI:10.1080/08941939.2025.2547226

Sicheng Zhou, Hongyu Xiang, Zehao Huang, Yue Teng, Wei Xing

{"title":"Feasibility and Prognostic Analysis of Neoadjuvant Therapy Followed by Breast-Conserving Surgery for Invasive Ductal Carcinoma Combined with Ductal Carcinoma in Situ.","authors":"Sicheng Zhou, Hongyu Xiang, Zehao Huang, Yue Teng, Wei Xing","doi":"10.1080/08941939.2025.2547226","DOIUrl":null,"url":null,"abstract":"Objective: This study aim to investigate the oncological safety of neoadjuvant therapy (NAT) followed by breast-conserving surgery (BCS) for invasive ductal carcinoma (IDC) patients with the presence of ductal carcinoma in situ (DCIS) on pre-NAT biopsy.Methods: The data of women with IDC who underwent radical surgery between January 2013 and December 2021 were retrospectively reviewed from two institutions. The study endpoints were 5-year disease-free survival (DFS) and local recurrence-fee survival (LRFS).Results: Overall, 994 eligible patients were enrolled. Patients with IDC with DCIS (n = 277) and patients undergoing BCS (n = 285) were selected separately for prognostic analysis. For patients with IDC with DCIS, the 5-year DFS (p = 0.517) and 5-year LRFS (p = 0.397) rates of the patients undergoing BCS were similar to those of patients undergoing mastectomy after propensity score matching. In addition, the 285 patients who underwent BCS were divided into the IDC + DCIS and IDC groups. The 5-year DFS (p = 0.394) and 5-year LRFS (p = 0.341) rates were similar between the IDC and IDC + DCIS groups.Conclusion: NAT followed by BCS combined with adjuvant radiotherapy is a safe and feasible treatment option in patients with IDC with DCIS under the premise of strict adherence to the surgical indications and adequate incision margins.","PeriodicalId":16200,"journal":{"name":"Journal of Investigative Surgery","volume":"38 1","pages":"2547226"},"PeriodicalIF":3.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Investigative Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08941939.2025.2547226","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aim to investigate the oncological safety of neoadjuvant therapy (NAT) followed by breast-conserving surgery (BCS) for invasive ductal carcinoma (IDC) patients with the presence of ductal carcinoma in situ (DCIS) on pre-NAT biopsy.

Methods: The data of women with IDC who underwent radical surgery between January 2013 and December 2021 were retrospectively reviewed from two institutions. The study endpoints were 5-year disease-free survival (DFS) and local recurrence-fee survival (LRFS).

Results: Overall, 994 eligible patients were enrolled. Patients with IDC with DCIS (n = 277) and patients undergoing BCS (n = 285) were selected separately for prognostic analysis. For patients with IDC with DCIS, the 5-year DFS (p = 0.517) and 5-year LRFS (p = 0.397) rates of the patients undergoing BCS were similar to those of patients undergoing mastectomy after propensity score matching. In addition, the 285 patients who underwent BCS were divided into the IDC + DCIS and IDC groups. The 5-year DFS (p = 0.394) and 5-year LRFS (p = 0.341) rates were similar between the IDC and IDC + DCIS groups.

Conclusion: NAT followed by BCS combined with adjuvant radiotherapy is a safe and feasible treatment option in patients with IDC with DCIS under the premise of strict adherence to the surgical indications and adequate incision margins.

查看原文本刊更多论文

浸润性导管癌合并导管原位癌新辅助治疗后保乳手术的可行性及预后分析。

目的：探讨新辅助治疗（NAT）后保乳手术（BCS）对浸润性导管癌（IDC）术前活检存在导管原位癌（DCIS）患者的肿瘤学安全性。方法：回顾性分析两家机构2013年1月至2021年12月间行根治性手术的女性IDC患者的资料。研究终点为5年无病生存（DFS）和局部复发费生存（LRFS）。结果：共纳入994例符合条件的患者。分别选择IDC合并DCIS患者（n = 277）和BCS患者（n = 285）进行预后分析。对于IDC合并DCIS患者，经倾向评分匹配后，行BCS患者的5年DFS （p = 0.517）和5年LRFS （p = 0.397）率与行乳腺切除术患者相似。将285例行BCS的患者分为IDC + DCIS组和IDC组。IDC组和IDC + DCIS组的5年DFS （p = 0.394）和5年LRFS （p = 0.341）相似。结论：在严格遵守手术指征和适当切缘的前提下，NAT + BCS +辅助放疗是IDC合并DCIS患者安全可行的治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Investigative Surgery 医学-外科

CiteScore

4.20

自引率

0.00%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Journal of Investigative Surgery publishes peer-reviewed scientific articles for the advancement of surgery, to the ultimate benefit of patient care and rehabilitation. It is the only journal that encompasses the individual and collaborative efforts of scientists in human and veterinary medicine, dentistry, basic and applied sciences, engineering, and law and ethics. The journal is dedicated to the publication of outstanding articles of interest to the surgical research community.